Notification of Interim Results

RNS Number : 6327R

ReNeuron Group plc

21 November 2012

 



21 November 2012

AIM: RENE

ReNeuron Group plc

("ReNeuron" or "the Company")

Notification of Interim Results

Guildford, UK, 21 November 2012: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell company, will announce its interim results for the six months ended 30 September 2012 on Tuesday 4 December 2012.

A meeting for analysts will be held at 10am on the day of the results at the offices of Buchanan, 107 Cheapside, London, EC2V 6DN.

For a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 10am on the day of the results: http://mediaserve.buchanan.uk.com/2012/reneuron041212/registration.asp.

A recording of the webcast will be made available on ReNeuron's and Buchanan's websites, www.reneuron.com and www.buchanan.uk.com.

- Ends -

Enquiries:

ReNeuron	[phone]
Michael Hunt, Chief Executive Officer
Dr John Sinden, Chief Scientific Officer
Buchanan	[phone]
Mark Court, Fiona Henson, Sophie Cowles
Cenkos Securities	[phone]
Stephen Keys, Adrian Hargrave (NOMAD and Broker)
Andy Roberts (Sales)

About ReNeuron

ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development.  The Company is also developing stem cell therapies for other conditions such as critical limb ischaemia, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina such as retinitis pigmentosa.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell^®products for use in academic and commercial research.  The Company's ReNcell^®CX and ReNcell^®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

 

END

 

 

NOREAXFEASLAFFF